Published in Endocr Metab Immune Disord Drug Targets on June 01, 2010
Fenofibrate and metabolic syndrome. Endocr Metab Immune Disord Drug Targets (2010) 1.01
Cardiovascular disease: the other face of diabetes. CPT Pharmacometrics Syst Pharmacol (2013) 0.76
Third Report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III) final report. Circulation (2002) 76.93
Seventh report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure. Hypertension (2003) 63.78
Association of glycaemia with macrovascular and microvascular complications of type 2 diabetes (UKPDS 35): prospective observational study. BMJ (2000) 35.06
Effect of rosiglitazone on the risk of myocardial infarction and death from cardiovascular causes. N Engl J Med (2007) 33.21
Prevalence of the metabolic syndrome among US adults: findings from the third National Health and Nutrition Examination Survey. JAMA (2002) 25.68
The metabolic syndrome--a new worldwide definition. Lancet (2005) 23.51
Mechanisms controlling mitochondrial biogenesis and respiration through the thermogenic coactivator PGC-1. Cell (1999) 19.48
The metabolic syndrome and total and cardiovascular disease mortality in middle-aged men. JAMA (2002) 18.43
The glucose fatty-acid cycle. Its role in insulin sensitivity and the metabolic disturbances of diabetes mellitus. Lancet (1963) 16.71
Overweight, obesity, and mortality in a large prospective cohort of persons 50 to 71 years old. N Engl J Med (2006) 16.17
C-reactive protein, interleukin 6, and risk of developing type 2 diabetes mellitus. JAMA (2001) 15.85
High density lipoprotein as a protective factor against coronary heart disease. The Framingham Study. Am J Med (1977) 15.39
Mammalian mitogen-activated protein kinase signal transduction pathways activated by stress and inflammation. Physiol Rev (2001) 13.15
Obesity and the risk of heart failure. N Engl J Med (2002) 12.58
Metabolic control through the PGC-1 family of transcription coactivators. Cell Metab (2005) 11.66
Reversal of obesity- and diet-induced insulin resistance with salicylates or targeted disruption of Ikkbeta. Science (2001) 11.56
Cause-specific excess deaths associated with underweight, overweight, and obesity. JAMA (2007) 11.50
Local and systemic insulin resistance resulting from hepatic activation of IKK-beta and NF-kappaB. Nat Med (2005) 10.88
Outcome of heart failure with preserved ejection fraction in a population-based study. N Engl J Med (2006) 10.58
PPAR gamma is required for placental, cardiac, and adipose tissue development. Mol Cell (1999) 10.08
Fasting compared with nonfasting triglycerides and risk of cardiovascular events in women. JAMA (2007) 9.68
Annual deaths attributable to obesity in the United States. JAMA (1999) 8.62
Rosiglitazone evaluated for cardiovascular outcomes in oral agent combination therapy for type 2 diabetes (RECORD): a multicentre, randomised, open-label trial. Lancet (2009) 8.54
PPARgamma promotes monocyte/macrophage differentiation and uptake of oxidized LDL. Cell (1998) 7.91
Metabolic syndrome and risk of incident cardiovascular events and death: a systematic review and meta-analysis of longitudinal studies. J Am Coll Cardiol (2007) 7.79
Impact of the metabolic syndrome on mortality from coronary heart disease, cardiovascular disease, and all causes in United States adults. Circulation (2004) 7.77
Association of fibrinogen, C-reactive protein, albumin, or leukocyte count with coronary heart disease: meta-analyses of prospective studies. JAMA (1998) 7.67
PPAR gamma mediates high-fat diet-induced adipocyte hypertrophy and insulin resistance. Mol Cell (1999) 7.56
The progression from hypertension to congestive heart failure. JAMA (1996) 7.56
Associations of elevated interleukin-6 and C-reactive protein levels with mortality in the elderly. Am J Med (1999) 6.92
PGC-1 coactivators: inducible regulators of energy metabolism in health and disease. J Clin Invest (2006) 6.85
The obesity paradox: body mass index and outcomes in patients with heart failure. Arch Intern Med (2005) 5.86
Oxidized LDL regulates macrophage gene expression through ligand activation of PPARgamma. Cell (1998) 5.78
Metabolic syndrome with and without C-reactive protein as a predictor of coronary heart disease and diabetes in the West of Scotland Coronary Prevention Study. Circulation (2003) 5.70
Elevated circulating levels of tumor necrosis factor in severe chronic heart failure. N Engl J Med (1990) 5.65
Lipotoxic heart disease in obese rats: implications for human obesity. Proc Natl Acad Sci U S A (2000) 5.65
Predictors of congestive heart failure in the elderly: the Cardiovascular Health Study. J Am Coll Cardiol (2000) 5.59
Diabetes mellitus, coronary heart disease incidence, and death from all causes in African American and European American women: The NHANES I epidemiologic follow-up study. J Clin Epidemiol (2000) 5.49
Abdominal obesity and the metabolic syndrome: contribution to global cardiometabolic risk. Arterioscler Thromb Vasc Biol (2008) 5.19
NCEP-defined metabolic syndrome, diabetes, and prevalence of coronary heart disease among NHANES III participants age 50 years and older. Diabetes (2003) 5.11
Mechanism by which high-dose aspirin improves glucose metabolism in type 2 diabetes. J Clin Invest (2002) 4.96
Leptin reverses insulin resistance and hepatic steatosis in patients with severe lipodystrophy. J Clin Invest (2002) 4.75
Recombinant leptin for weight loss in obese and lean adults: a randomized, controlled, dose-escalation trial. JAMA (1999) 4.71
Association of the metabolic syndrome with history of myocardial infarction and stroke in the Third National Health and Nutrition Examination Survey. Circulation (2003) 4.52
The metabolic syndrome and 11-year risk of incident cardiovascular disease in the atherosclerosis risk in communities study. Diabetes Care (2005) 4.38
The cardiac phenotype induced by PPARalpha overexpression mimics that caused by diabetes mellitus. J Clin Invest (2002) 4.22
Thiazolidinediones expand body fluid volume through PPARgamma stimulation of ENaC-mediated renal salt absorption. Nat Med (2005) 4.14
PPARalpha and PPARgamma activators direct a distinct tissue-specific transcriptional response via a PPRE in the lipoprotein lipase gene. EMBO J (1996) 4.11
Inflammatory markers and risk of heart failure in elderly subjects without prior myocardial infarction: the Framingham Heart Study. Circulation (2003) 4.09
Regional distribution of body fat, plasma lipoproteins, and cardiovascular disease. Arteriosclerosis (1990) 4.01
A paracrine loop between adipocytes and macrophages aggravates inflammatory changes: role of free fatty acids and tumor necrosis factor alpha. Arterioscler Thromb Vasc Biol (2005) 3.98
Association of overweight with increased risk of coronary heart disease partly independent of blood pressure and cholesterol levels: a meta-analysis of 21 cohort studies including more than 300 000 persons. Arch Intern Med (2007) 3.97
Restoration of insulin-sensitive glucose transporter (GLUT4) gene expression in muscle cells by the transcriptional coactivator PGC-1. Proc Natl Acad Sci U S A (2001) 3.96
Risk factors for the progression of coronary artery calcification in asymptomatic subjects: results from the Multi-Ethnic Study of Atherosclerosis (MESA). Circulation (2007) 3.90
Cardiac steatosis in diabetes mellitus: a 1H-magnetic resonance spectroscopy study. Circulation (2007) 3.88
Fatty liver: a novel component of the metabolic syndrome. Arterioscler Thromb Vasc Biol (2007) 3.83
CD36 deficiency associated with insulin resistance. Lancet (2001) 3.82
Diabetic cardiomyopathy: evidence, mechanisms, and therapeutic implications. Endocr Rev (2004) 3.69
Heritability of type II (non-insulin-dependent) diabetes mellitus and abnormal glucose tolerance--a population-based twin study. Diabetologia (1999) 3.64
Proinflammatory cytokine levels in patients with depressed left ventricular ejection fraction: a report from the Studies of Left Ventricular Dysfunction (SOLVD). J Am Coll Cardiol (1996) 3.47
Prospective study of sudden cardiac death among women in the United States. Circulation (2003) 3.45
Myocardial steatosis is an independent predictor of diastolic dysfunction in type 2 diabetes mellitus. J Am Coll Cardiol (2008) 3.43
The expression of tumor necrosis factor in human adipose tissue. Regulation by obesity, weight loss, and relationship to lipoprotein lipase. J Clin Invest (1995) 3.39
Targeted anticytokine therapy in patients with chronic heart failure: results of the Randomized Etanercept Worldwide Evaluation (RENEWAL). Circulation (2004) 3.30
Cardiovascular mortality in overweight subjects: the key role of associated risk factors. Hypertension (2005) 3.27
Diabetic cardiomyopathy: the search for a unifying hypothesis. Circ Res (2006) 3.27
Trends in all-cause and cardiovascular disease mortality among women and men with and without diabetes mellitus in the Framingham Heart Study, 1950 to 2005. Circulation (2009) 3.23
Outcome of congestive heart failure in elderly persons: influence of left ventricular systolic function. The Cardiovascular Health Study. Ann Intern Med (2002) 3.17
Hypertension and associated metabolic abnormalities--the role of insulin resistance and the sympathoadrenal system. N Engl J Med (1996) 3.07
Peroxisome proliferator-activated receptors (PPARs): nuclear receptors at the crossroads between lipid metabolism and inflammation. Inflamm Res (2000) 3.02
Toll4 (TLR4) expression in cardiac myocytes in normal and failing myocardium. J Clin Invest (1999) 2.94
Homeostasis model assessment of insulin resistance in relation to the incidence of cardiovascular disease: the San Antonio Heart Study. Diabetes Care (2002) 2.92
Metabolic syndrome amplifies the age-associated increases in vascular thickness and stiffness. J Am Coll Cardiol (2004) 2.91
Hypertensive myocardial fibrosis and diastolic dysfunction: another model of inflammation? Hypertension (2004) 2.89
Left ventricular mass predicts heart failure not related to previous myocardial infarction: the Cardiovascular Health Study. Eur Heart J (2008) 2.85
Plasma triglyceride level and mortality from coronary heart disease. N Engl J Med (1993) 2.80
Effects of weight reduction on blood lipids and lipoproteins: a meta-analysis. Am J Clin Nutr (1992) 2.78
Patients with early diabetic heart disease demonstrate a normal myocardial response to dobutamine. J Am Coll Cardiol (2003) 2.76
A critical role for PPARalpha-mediated lipotoxicity in the pathogenesis of diabetic cardiomyopathy: modulation by dietary fat content. Proc Natl Acad Sci U S A (2003) 2.68
Improved insulin-sensitivity in mice heterozygous for PPAR-gamma deficiency. J Clin Invest (2000) 2.67
Peroxisome proliferator-activated receptors in inflammation control. J Endocrinol (2001) 2.66
National Cholesterol Education Program versus World Health Organization metabolic syndrome in relation to all-cause and cardiovascular mortality in the San Antonio Heart Study. Circulation (2004) 2.65
Angiotensin type 1 receptor blockers induce peroxisome proliferator-activated receptor-gamma activity. Circulation (2004) 2.64
Deletion of PPARgamma in adipose tissues of mice protects against high fat diet-induced obesity and insulin resistance. Proc Natl Acad Sci U S A (2005) 2.60
Selective cooperation between fatty acid binding proteins and peroxisome proliferator-activated receptors in regulating transcription. Mol Cell Biol (2002) 2.58
Transgenic expression of fatty acid transport protein 1 in the heart causes lipotoxic cardiomyopathy. Circ Res (2004) 2.50
The impact of obesity on left ventricular mass and geometry. The Framingham Heart Study. JAMA (1991) 2.44
Effects of cholesterol and inflammation-sensitive plasma proteins on incidence of myocardial infarction and stroke in men. Circulation (2002) 2.44
Failure of fat cell proliferation, mitochondrial function and fat oxidation results in ectopic fat storage, insulin resistance and type II diabetes mellitus. Int J Obes Relat Metab Disord (2004) 2.40
Visceral obesity in men. Associations with glucose tolerance, plasma insulin, and lipoprotein levels. Diabetes (1992) 2.36
Involvement of extracellular signal-regulated kinases 1/2 in cardiac hypertrophy and cell death. Circ Res (2002) 2.35
Use of thiazolidinediones and risk of heart failure in people with type 2 diabetes: a retrospective cohort study. Diabetes Care (2003) 2.29
Human metabolic syndrome resulting from dominant-negative mutations in the nuclear receptor peroxisome proliferator-activated receptor-gamma. Diabetes (2003) 2.28
Angiotensin II-accelerated atherosclerosis and aneurysm formation is attenuated in osteopontin-deficient mice. J Clin Invest (2003) 2.23
Heart disease and stroke statistics--2011 update: a report from the American Heart Association. Circulation (2010) 30.07
Heart disease and stroke statistics--2015 update: a report from the American Heart Association. Circulation (2014) 22.74
Defining and setting national goals for cardiovascular health promotion and disease reduction: the American Heart Association's strategic Impact Goal through 2020 and beyond. Circulation (2010) 13.28
Heart Disease and Stroke Statistics-2016 Update: A Report From the American Heart Association. Circulation (2015) 10.14
Vascular contributions to cognitive impairment and dementia: a statement for healthcare professionals from the american heart association/american stroke association. Stroke (2011) 10.11
Mixed linear model approach adapted for genome-wide association studies. Nat Genet (2010) 8.47
Criteria for evaluation of novel markers of cardiovascular risk: a scientific statement from the American Heart Association. Circulation (2009) 8.11
Overweight in children and adolescents: pathophysiology, consequences, prevention, and treatment. Circulation (2005) 7.04
Usual versus tight control of systolic blood pressure in non-diabetic patients with hypertension (Cardio-Sis): an open-label randomised trial. Lancet (2009) 6.25
A genome-wide association study for blood lipid phenotypes in the Framingham Heart Study. BMC Med Genet (2007) 5.64
The relationship between visit-to-visit variability in systolic blood pressure and all-cause mortality in the general population: findings from NHANES III, 1988 to 1994. Hypertension (2011) 5.14
Common missense variant in the glucokinase regulatory protein gene is associated with increased plasma triglyceride and C-reactive protein but lower fasting glucose concentrations. Diabetes (2008) 4.20
Alterations in left ventricular structure and function in young healthy obese women: assessment by echocardiography and tissue Doppler imaging. J Am Coll Cardiol (2004) 2.97
Traditional cardiovascular risk factors in relation to left ventricular mass, volume, and systolic function by cardiac magnetic resonance imaging: the Multiethnic Study of Atherosclerosis. J Am Coll Cardiol (2006) 2.94
Executive Summary: Heart Disease and Stroke Statistics-2016 Update: A Report From the American Heart Association. Circulation (2016) 2.87
Fenofibrate effect on triglyceride and postprandial response of apolipoprotein A5 variants: the GOLDN study. Arterioscler Thromb Vasc Biol (2007) 2.54
Chocolate consumption is inversely associated with prevalent coronary heart disease: the National Heart, Lung, and Blood Institute Family Heart Study. Clin Nutr (2010) 2.40
Differences in left ventricular structure between black and white hypertensive adults: the Hypertension Genetic Epidemiology Network study. Hypertension (2004) 2.36
Genetic loci associated with plasma phospholipid n-3 fatty acids: a meta-analysis of genome-wide association studies from the CHARGE Consortium. PLoS Genet (2011) 2.33
Genetic ancestry is associated with subclinical cardiovascular disease in African-Americans and Hispanics from the multi-ethnic study of atherosclerosis. Circ Cardiovasc Genet (2009) 2.31
Cardiac remodeling in obesity. Circ Cardiovasc Imaging (2013) 2.24
Kidney function influences warfarin responsiveness and hemorrhagic complications. J Am Soc Nephrol (2009) 2.13
Trends in blood pressure, hypertension control, and stroke mortality: the Minnesota Heart Survey. Am J Med (2006) 2.10
Genetic variants associated with cardiac structure and function: a meta-analysis and replication of genome-wide association data. JAMA (2009) 2.10
Markers of inflammation, metabolic risk factors, and incident heart failure in American Indians: the Strong Heart Study. J Clin Hypertens (Greenwich) (2011) 2.04
The -256T>C polymorphism in the apolipoprotein A-II gene promoter is associated with body mass index and food intake in the genetics of lipid lowering drugs and diet network study. Clin Chem (2007) 2.03
Dietary linolenic acid is inversely associated with calcified atherosclerotic plaque in the coronary arteries: the National Heart, Lung, and Blood Institute Family Heart Study. Circulation (2005) 2.03
Impact of obesity on cardiac geometry and function in a population of adolescents: the Strong Heart Study. J Am Coll Cardiol (2006) 2.00
Hypertension and smoking are associated with reduced regional left ventricular function in asymptomatic: individuals the Multi-Ethnic Study of Atherosclerosis. J Am Coll Cardiol (2006) 1.98
Initial left-ventricular mass predicts probability of uncontrolled blood pressure in arterial hypertension. J Hypertens (2011) 1.97
Influence of CYP2C9 and VKORC1 on warfarin dose, anticoagulation attainment and maintenance among European-Americans and African-Americans. Pharmacogenomics (2008) 1.89
A meta-analysis identifies new loci associated with body mass index in individuals of African ancestry. Nat Genet (2013) 1.82
Cardiac markers of pre-clinical disease in adolescents with the metabolic syndrome: the strong heart study. J Am Coll Cardiol (2008) 1.81
Prognostic effect of inappropriately high left ventricular mass in asymptomatic severe aortic stenosis. Heart (2010) 1.80
Stroke Genetics Network (SiGN) study: design and rationale for a genome-wide association study of ischemic stroke subtypes. Stroke (2013) 1.80
Prevalence and prognostic significance of wall-motion abnormalities in adults without clinically recognized cardiovascular disease: the Strong Heart Study. Circulation (2007) 1.78
Genome-wide meta-analysis points to CTC1 and ZNF676 as genes regulating telomere homeostasis in humans. Hum Mol Genet (2012) 1.77
Apolipoprotein E polymorphisms and postprandial triglyceridemia before and after fenofibrate treatment in the Genetics of Lipid Lowering and Diet Network (GOLDN) Study. Circ Cardiovasc Genet (2010) 1.77
Comparison of the Framingham Heart Study hypertension model with blood pressure alone in the prediction of risk of hypertension: the Multi-Ethnic Study of Atherosclerosis. Hypertension (2010) 1.75
Metabolic syndrome is associated with abnormal left ventricular diastolic function independent of left ventricular mass. Eur Heart J (2007) 1.66
Relationship between left ventricular geometry and left atrial size and function in patients with systemic hypertension. J Hypertens (2004) 1.65
VKORC1 polymorphisms, haplotypes and haplotype groups on warfarin dose among African-Americans and European-Americans. Pharmacogenomics (2008) 1.65
Improved cardiovascular diagnostic accuracy by pocket size imaging device in non-cardiologic outpatients: the NaUSiCa (Naples Ultrasound Stethoscope in Cardiology) study. Cardiovasc Ultrasound (2010) 1.64
Genome scan of glomerular filtration rate and albuminuria: the HyperGEN study. Nephrol Dial Transplant (2006) 1.59
Quantitative-trait loci influencing body-mass index reside on chromosomes 7 and 13: the National Heart, Lung, and Blood Institute Family Heart Study. Am J Hum Genet (2001) 1.59
Relationship of interleukin-6 with regional and global left-ventricular function in asymptomatic individuals without clinical cardiovascular disease: insights from the Multi-Ethnic Study of Atherosclerosis. Eur Heart J (2010) 1.58
Impaired inotropic response in type 2 diabetes mellitus: a strain rate imaging study. Am J Hypertens (2007) 1.57
Trans-ethnic fine-mapping of lipid loci identifies population-specific signals and allelic heterogeneity that increases the trait variance explained. PLoS Genet (2013) 1.57
Pharmacogenetic association of hypertension candidate genes with fasting glucose in the GenHAT Study. J Hypertens (2010) 1.55
A summary of the effects of antihypertensive medications on measured blood pressure. Am J Hypertens (2005) 1.55
Health-related quality of life and survival in liver transplant candidates. Liver Transpl (2010) 1.55
Trends in the trans-fatty acid composition of the diet in a metropolitan area: the Minnesota Heart Survey. J Am Diet Assoc (2003) 1.54
Excessive increase in left ventricular mass identifies hypertensive subjects with clustered geometric and functional abnormalities. J Hypertens (2007) 1.52
Aortic valve sclerosis is associated with preclinical cardiovascular disease in hypertensive adults: the Hypertension Genetic Epidemiology Network study. J Hypertens (2005) 1.49
Effects of losartan compared with atenolol on lipids in patients with hypertension and left ventricular hypertrophy: the Losartan Intervention For Endpoint reduction in hypertension study. J Hypertens (2009) 1.48
Comparison of cardiac structure and function in American Indians with and without the metabolic syndrome (the Strong Heart Study). Am J Cardiol (2004) 1.48
Hypertensive target organ damage predicts incident diabetes mellitus. Eur Heart J (2013) 1.47
Assessment of the interaction of heritability of volume load and left ventricular mass: the HyperGEN offspring study. J Hypertens (2007) 1.46
Clinical impact of 'in-treatment' wall motion abnormalities in hypertensive patients with left ventricular hypertrophy: the LIFE study. J Hypertens (2008) 1.46
Family history of premature coronary heart disease and coronary artery calcification: Multi-Ethnic Study of Atherosclerosis (MESA). Circulation (2007) 1.44
Left atrial systolic force in hypertensive patients with left ventricular hypertrophy: the LIFE study. J Hypertens (2008) 1.44
Hemodynamic and echocardiographic profiles in African American compared with White offspring of hypertensive parents: the HyperGEN study. Am J Hypertens (2013) 1.43
Prognostic value of serial electrocardiographic voltage and repolarization changes in essential hypertension: the HEART Survey study. Am J Hypertens (2007) 1.43
Linkage of the cholesterol 7alpha-hydroxylase gene and low-density lipoprotein cholesterol conditional on apolipoprotein E association: the National Heart, Lung, and Blood Institute Family Heart Study. Chin Med J (Engl) (2005) 1.42
Lifestyle determinants of high-density lipoprotein cholesterol: the National Heart, Lung, and Blood Institute Family Heart Study. Am Heart J (2004) 1.41
Myocardial fatty acid metabolism: independent predictor of left ventricular mass in hypertensive heart disease. Hypertension (2003) 1.39
[Hypertensive heart disease: diagnostic and therapeutic guidelines]. G Ital Cardiol (Rome) (2008) 1.39
Method errors or unexplained biological information? Hypertension (2010) 1.38
Relations of pulse pressure and other components of blood pressure to preclinical echocardiographic abnormalities. J Hypertens (2002) 1.38
Serial echocardiographic assessment of left ventricular mass: how blinded should readers be? J Hypertens (2004) 1.38
Alcohol consumption and metabolic syndrome: does the type of beverage matter? Obes Res (2004) 1.38
Epigenome-wide association study of fasting measures of glucose, insulin, and HOMA-IR in the Genetics of Lipid Lowering Drugs and Diet Network study. Diabetes (2013) 1.38
SNPs located at CpG sites modulate genome-epigenome interaction. Epigenetics (2013) 1.37
Left ventricular geometry in children with mild to moderate chronic renal insufficiency. J Am Soc Nephrol (2005) 1.36
Genome-wide meta-analysis of observational studies shows common genetic variants associated with macronutrient intake. Am J Clin Nutr (2013) 1.35
A genome-wide association study of inflammatory biomarker changes in response to fenofibrate treatment in the Genetics of Lipid Lowering Drug and Diet Network. Pharmacogenet Genomics (2012) 1.35
Effect of influenza vaccine on markers of inflammation and lipid profile. J Lab Clin Med (2005) 1.31
Prognostic significance of left ventricular diastolic dysfunction in essential hypertension. J Am Coll Cardiol (2002) 1.31
Association of kidney function and hemoglobin with left ventricular morphology among African Americans: the Atherosclerosis Risk in Communities (ARIC) study. Am J Kidney Dis (2004) 1.30
Pharmacogenetic association of the NPPA T2238C genetic variant with cardiovascular disease outcomes in patients with hypertension. JAMA (2008) 1.30
Metabolic syndrome and echocardiographic left ventricular mass in blacks: the Atherosclerosis Risk in Communities (ARIC) Study. Circulation (2005) 1.29
Normal limits in relation to age, body size and gender of two-dimensional echocardiographic aortic root dimensions in persons ≥15 years of age. Am J Cardiol (2012) 1.29
The PLIN4 variant rs8887 modulates obesity related phenotypes in humans through creation of a novel miR-522 seed site. PLoS One (2011) 1.28
Association of left ventricular hypertrophy with metabolic risk factors: the HyperGEN study. J Hypertens (2002) 1.27
An investigation of the effects of lipid-lowering medications: genome-wide linkage analysis of lipids in the HyperGEN study. BMC Genet (2007) 1.27
Cardiovascular and metabolic predictors of progression of prehypertension into hypertension: the Strong Heart Study. Hypertension (2009) 1.26
Accuracy of estimation of large food portions. J Am Diet Assoc (2004) 1.24
CLOCK genetic variation and metabolic syndrome risk: modulation by monounsaturated fatty acids. Am J Clin Nutr (2009) 1.24
Contribution of metabolic and anthropometric abnormalities to cardiovascular disease risk factors. Circulation (2008) 1.24
Linkage analysis of a composite factor for the multiple metabolic syndrome: the National Heart, Lung, and Blood Institute Family Heart Study. Diabetes (2003) 1.24
Impact of left ventricular geometry on prognosis in hypertensive patients with left ventricular hypertrophy (the LIFE study). Eur J Echocardiogr (2008) 1.23
Fruit and vegetable consumption and LDL cholesterol: the National Heart, Lung, and Blood Institute Family Heart Study. Am J Clin Nutr (2004) 1.23
Arterial stiffness is greater in African Americans than in whites: evidence from the Forsyth County, North Carolina, ARIC cohort. Am J Hypertens (2004) 1.22
Renin-angiotensin inhibition in systolic heart failure and chronic kidney disease. Am J Med (2012) 1.22
APOA2, dietary fat, and body mass index: replication of a gene-diet interaction in 3 independent populations. Arch Intern Med (2009) 1.22
A high intake of saturated fatty acids strengthens the association between the fat mass and obesity-associated gene and BMI. J Nutr (2011) 1.20
A genome-wide scan of pulmonary function measures in the National Heart, Lung, and Blood Institute Family Heart Study. Am J Respir Crit Care Med (2003) 1.19
A whole-genome scan for stroke or myocardial infarction in family blood pressure program families. Stroke (2008) 1.18
Comparison of ultracentrifugation and nuclear magnetic resonance spectroscopy in the quantification of triglyceride-rich lipoproteins after an oral fat load. Clin Chem (2004) 1.17